Latest Distribution Agreements News

Vitura Health has inked a binding distribution agreement with MedReleaf Australia, unlocking access to a broad medicinal cannabis portfolio across its extensive pharmacy network. This deal could add up to AUD 15 million annually, positioning Vitura as a dominant player in the evolving Australian market.

Heavy Minerals Limited has defined a substantial garnet exploration target at the Kanmantoo site in South Australia, estimating up to 50 million tonnes grading 17-25% garnet. The company is advancing metallurgical testing and funding discussions, positioning for a near-term investment decision.

First Graphene Limited has broadened its North American footprint by appointing SuperGrafeno as its distributor in Canada, targeting the country’s infrastructure sector with its innovative graphene-enhanced cement and concrete products.

Rhythm Biosciences has inked a pivotal distribution agreement with UK-based Digistain Limited to introduce its geneType™ genetic test portfolio in Southeast Asia, starting with the Philippines. This marks Rhythm’s first commercial foothold in the region, setting the stage for broader expansion.

Nuchev Limited has transitioned from an agency to a distribution model with H&S Global, aiming to enhance margins and scale growth across key wellness brands.

Control Bionics has secured a key regulatory milestone with its NeuroNode device now eligible for reimbursement under Germany’s statutory health insurance, paving the way for expanded European distribution.

Osteopore Limited has landed a two-year distribution deal for an innovative autologous dentin graft technology in Singapore, setting the stage for expansion across ASEAN and the wider Asia-Pacific dental market.

Terragen Holdings’ biostimulant Great Land Plus® has been independently shown to increase maize silage yields by up to 12%, translating into an estimated $1,100 additional revenue per hectare and a potential 20-fold return on investment.

RLF AgTech reported a 5% increase in revenue to $14.3 million for the half-year ending December 2025, while posting a $4.08 million loss reflecting a deliberate investment phase. The company also appointed Stuart Upton as CEO to lead its next growth chapter.

Aumake Limited reported a sharp 45% drop in half-year revenue alongside a 24% increase in net loss, while securing new capital and a major distribution deal to support its pivot in the China market.

Elanor Investors Group reported a $24.5 million net loss for the half year to December 2024, grappling with debt covenant breaches and defaults. The group has struck a $125 million recapitalisation agreement with Rockworth Capital Partners to stabilise its balance sheet and pursue growth.

Lumos Diagnostics reported a 74% increase in its half-year loss to US$4.88 million, despite strong progress with its FebriDx diagnostic test and a landmark US distribution agreement. The company awaits a critical FDA decision that could unlock significant revenue growth.